G01N 33/5052
Involving b-cells
Official title: {involving B-cells}
G01N33/5052 (Involving b-cells) appears on 147 US grants and 280 published applications in this corpus.
Search patents in G01N- Granted patents
- 147
- Published applications
- 280
- Assignees
- 159
- Inventors
- 543
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 2 |
| 2002 | 0 | 5 |
| 2003 | 2 | 6 |
| 2004 | 2 | 11 |
| 2005 | 3 | 11 |
| 2006 | 6 | 5 |
| 2007 | 2 | 12 |
| 2008 | 6 | 9 |
| 2009 | 4 | 9 |
| 2010 | 10 | 17 |
| 2011 | 7 | 15 |
| 2012 | 3 | 11 |
| 2013 | 3 | 11 |
| 2014 | 9 | 8 |
| 2015 | 7 | 12 |
| 2016 | 4 | 15 |
| 2017 | 7 | 17 |
| 2018 | 11 | 11 |
| 2019 | 8 | 16 |
| 2020 | 9 | 19 |
| 2021 | 12 | 12 |
| 2022 | 6 | 13 |
| 2023 | 9 | 8 |
| 2024 | 6 | 11 |
| 2025 | 4 | 11 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CD33 antibodies16 Jun 2026US 12,655,216 B2University of Florida Research Foundation, Inc.
- Comprehensive monoclonal antibody generation7 Apr 2026US 12,595,592 B2BioAtla, Inc.
- Compositions for determining vaccine potency24 Feb 2026US 12,560,606 B2BioMadison, Inc.
- Lymphocyte-based morphometric test for alzheimer's disease2 Sep 2025US 12,405,268 B2NeuroDiagnostics LLC
- Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same29 Jul 2025US 12,371,487 B2Regeneron Pharmaceuticals, Inc.
- Methods for modulating the function of biological regulatory networks in health and disease by exploiting their memory properties11 Jun 2026US 2026/0159801 A1
- Method for screening and preparing immunomodulator26 Feb 2026US 2026/0056186 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Biomarkers for allergen immunotherapy1 Jan 2026US 2026/0002930 A1Alfred Health
- Treatment of autoimmune diseases with engineered immune cells13 Nov 2025US 2025/0345424 A1Caribou Biosciences, Inc.
- Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same9 Oct 2025US 2025/0313624 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Human secreted proteins202US 7,368,531 B2Human Genome Sciences, Inc. · 2008
- Methods for screening for compounds that modulate pd-1 signaling113US 7,105,328 B2Dana-Farber Cancer Institute, Inc. · 2006
- Molecular recognition units104US 5,196,510 ACytogen Corporation · 1993
- Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-194US 7,709,214 B2Dana-Farber Cancer Institute, Inc. · 2010
- Screening assays and methods60US 7,776,553 B2Presidents and Fellows of Harvard College · 2010